Marina Du
Associate
Marina is a true believer in interdisciplinary thinking, global collaboration and never stop pivoting!
With a background in Corporate Innovation and Digital transformation, Marina has helped various F500 corporates commercialize frontier technologies, incubate new digital ventures and launch multi-year transformation programs. Prior to joining Hitachi Ventures, Marina led the Corporate Innovation practice at EY and built the investment thesis for Bits x Bites, the first food innovation VC in China. Marina is passionate about the intersection of tech and bio, and all things data pipeline. Marina holds a BA in Mathematics from St. Olaf College and obtained her MBA from INSEAD. She is also a certified Futurist by Palo Alto-based Institute for the Future.
Areas of Interest
- Data
- Digital Twin
- Industrial AI
- Life Science
- Robotics
- Techbio
Active Investments
Perspectives
View All
February 14, 2025
Why We Invested
Bioptimus: The GPT of Biology – Unlocking Deep Insights Across Biological Scales
January 14, 2025
Portfolio News
Bioptimus Hits $76M Funding Milestone and Prepares to Launch Groundbreaking Foundation Model for Biology
March 19, 2024
Portfolio News
Cure51 raises a €15M seed round aiming to crack the code on cancer survival
March 13, 2024
Portfolio News
Exclusive: ‘ChatGPT for DNA’: Relation nabs $35M, with Nvidia backing, for osteoporosis work
Bioptimus is building a universal multi-scale, multi-modal Foundation Model for Biology to revolutionize biomedicine research.
Bioptimus is building the world’s first universal multi-scale, multi-modal Foundation Model for Biology. By leveraging expertise from Google DeepMind and the unique MOSAIC dataset, Bioptimus aims to uncover intricate relationships across biological systems at unprecedented scales. This groundbreaking approach is poised to drive the next frontier in biomedicine research.
CEO
Jean-Philippe Vert
Sectors
Digital
Healthcare
Stage
Series A
HQ
Paris
Deal Team
Wolfgang Seibold
Joanna Soroka
Marina Du
Aditi Purandare
Cure51 is building the first global database of cancer survivors to uncover new life-saving medicines.
Cure51 is creating the world’s first global, diversified clinical and molecular database of cancer survivors to uncover life-saving medicines. Through a collaborative network, multiomics, and special biology, it aims to identify therapeutic targets for cancer treatment. The company, co-created with oncology centers, focuses on three cancer indications.
CEO
Nicolas Wolikow
Sectors
Healthcare
Stage
Seed
HQ
Paris
Deal Team
Wolfgang Seibold
Joanna Soroka
Marina Du
Relation Therapeutics combines AI, genomic medicine, and Lab-in-the-Loop to build disease maps and discover novel drug targets.
Relation Therapeutics is a drug discovery company focused on genomics, combining advanced ActiveGraph AI models with Lab-in-the-Loop. This integration allows for seamless single-cell analysis at scale, creating rich maps of disease biology to identify novel drug targets. Their approach accelerates drug discovery by linking genomics and AI-driven insights.
CEO
David Roblin
Sectors
Digital
Healthcare
Stage
Seed
HQ
London
Deal Team
Wolfgang Seibold
Joanna Soroka
Marina Du
